Photys Therapeutics Stock

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.

Sign up today and learn more about Photys Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Photys Therapeutics Stock

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler, Salk’s Tony Hunter, Berkeley’s Dan Nomura, MPM’s Wendy Young, and Dana Farber’s Eric Fischer.

Funding History

September 2022$75.0M

Management

Board of Directors

Lizzie Ngo

Board of Directors

Otello Stampacchia

Board of Directors

David Steinberg

Board of Directors

Briggs Morrison

Board of Directors

Luke Evnin

Board of Directors

Alon Lazarus

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo